Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2023-10-19 00:00:00 ET · period of report 2023-10-18 · accession 0001104659-23-110157 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-19 | 2023-10-18 | PTGX | PATEL DINESH V PH D | Pres, CEO, Dir | M - OptEx | $4.21 | +6,000 | 609.3K | +1.0% | +$25.3K |
| D | 2023-10-19 | 2023-10-18 | PTGX | PATEL DINESH V PH D | Pres, CEO, Dir | M - OptEx | $0.00 | -6,000 | 54.0K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-18 | M | A | 6,000 | $4.21 | 609,347 | D | — | — | (F1) Includes an aggregate of 401 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2023. |
| 2 | Derivative | Stock Option (right to buy) | 2023-10-18 | M | D | 6,000 | $0.00 | 54,000 | D | $4.21 · — to 2026-04-29 | 6,000 Common Stock | (F2) These stock options are fully vested. |